| Literature DB >> 28430160 |
Simona John Von Freyend1, Terry Kwok-Schuelein2,3, Hans J Netter4,5, Gholamreza Haqshenas6, Jean-Philippe Semblat7, Christian Doerig8.
Abstract
Intracellular pathogens have evolved a wide range of strategies to not only escape from the immune systems of their hosts, but also to directly exploit a variety of host factors to facilitate the infection process. One such strategy is to subvert host cell signalling pathways to the advantage of the pathogen. Recent research has highlighted that the human serine/threonine kinase PAK, or p21-activated kinase, is a central component of host-pathogen interactions in many infection systems involving viruses, bacteria, and eukaryotic pathogens. PAK paralogues are found in most mammalian tissues, where they play vital roles in a wide range of functions. The role of PAKs in cell proliferation and survival, and their involvement in a number of cancers, is of great interest in the context of drug discovery. In this review we discuss the latest insights into the surprisingly central role human PAK1 plays for the infection by such different infectious disease agents as viruses, bacteria, and parasitic protists. It is our intention to open serious discussion on the applicability of PAK inhibitors for the treatment, not only of neoplastic diseases, which is currently the primary objective of drug discovery research targeting these enzymes, but also of a wide range of infectious diseases.Entities:
Keywords: bacteria; host-pathogen interactions; kinase; parasite; signalling; virus
Year: 2017 PMID: 28430160 PMCID: PMC5488651 DOI: 10.3390/pathogens6020017
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Schematic of the activation mechanism of PAK1.
Figure 2Pathogens of all three classes—virus, bacteria and parasitic protists—modulate host PAK1 signalling for a diverse range of purposes. For pathogens listed with a “?” there is so far no direct evidence available for the involvement of PAK1 in diverting host cell signalling to the pathogen’s advantage. However, circumstantial evidence points to a likely involvement of host PAK1 in the respective processes, which led to inclusion in this review.
Activation of signalling pathways utilizing PAK1 by pathogens; only pathways for which two or more components are known were included in this table.
| Name of Pathogen | Pathogen Type | Effect on PAK1 | Pathogen Mediator | Involved Pathway Components | Outcome | Pathogen Process | References |
|---|---|---|---|---|---|---|---|
| HIV | RNA virus | Activation | Nef | PAK1, PAK2, PI3K, BAD | Anti-apoptotic | Pathogen survival | [ |
| Activation | gp120 | Rac1, PAK1, LIMK1 | Actin polymerization | Invasion | [ | ||
| HBV | DNA virus | Upregulation | HBx | PAK1 | Anti-apoptotic (Anti-Anoikis) | Pathogen survival | [ |
| Human herpes virus 8 (HHV-8) | DNA virus | Activation | GPCR | Rac1, Cdc42, PAK1, IKKβ, IκB, NF-κB | Cellular transformation to Kaposi’s sarcoma | Pathogen survival | [ |
| Not known | Rac1, PAK1, (VE)-cadherin, β-catenin | Disassembly of cell junctions, enhanced vascular permeability | Cytoskeletal changes independent of invasion | [ | |||
| Alphaherpes-virus | DNA virus | Activation | US3 | PAK1, Bad, Bid | Anti-apoptotic, protection against NK cells | Pathogen survival | [ |
| Activation | US3 | PAK1, cofilin | Breakdown of actin stress fibres, formation of actin dependent cell projections | Cytoskeletal changes independent of invasion | [ | ||
| Influenza A | RNA virus | Activation | Not known | PAK1, MEK1 | Higher viral titres | Pathogen development | [ |
| EPEC | Bacteria | Activation | T3SS effector protein EspG | PAK1, PAK2 | Not known | Not known | [ |
| Bacteria | Activation | Not known | Rac1, Cdc42, PAK1 | Formation of filopodia and lamellipodia | Cytoskeletal changes | [ | |
| Bacteria | Activation | Not known | AP-1, JNK, Rac1, Cdc42, PAK2, PAK1 | Inflammatory response | Host nuclear response | [ | |
| Bacteria | Activation | T4SS effector protein CagA | PAK1, NIK, IKKs, NF-kB | Inflammatory responses | Host nuclear response | [ | |
| Activation | T4SS effector(s) | Rac1, PAK1 | Increased motility of host cell | Cytoskeletal changes independent of invasion | [ | ||
| Bacteria | Inactivation | Not known | MLCK, PAK1 | Actin-mediated internalisation | Invasion | [ | |
| Non-typeable | Bacteria | Activation | Not known | Rac1, PI3K, PAK1, Op18/stathmin | Microtubule polymerization | Invasion | [ |
| Bacteria | Activation | T3SS effectors proteins SopB, SopE, SopE2 | GTPases, PAK1, c-Abl, STAT3 | Intracellular growth of the pathogen | Pathogen development | [ | |
| Parasite | Activation? | PDNF | PAK1, Akt | Anti-apoptotic | Pathogen survival | [ | |
| Parasite | Activation | Not known | PAK1, MEK1 | Parasite survival | Pathogen development | [ | |
| Parasite | upregulation | Not known | IKK, IκB, NFκB, PAK1 | Host cellular transformation | Host nuclear response | [ |
Pathogen entry into host cells by PAK1-mediated macropinocytosis; all signalling components listed are human proteins, unless otherwise noted.
| Pathogen | Type of Pathogen | Cell Factor (Receptor) | Known Pathway Components | Effector of PAK1/Function | References |
|---|---|---|---|---|---|
| A-MLV | RNA virus | Rac1, PAK1, RhoG | [ | ||
| Echovirus 1 | RNA virus | α2β1 integrin | PI3K, PLC, PKCα, Rac1, PAK1 | CtBP-1/BARS, Macropinosome closure | [ |
| FMDV | RNA virus | αvβ1, αvβ3, αvβ6, αvβ8 integrin | RTK, Rac1, PAK1, | [ | |
| Ebola virus | RNA virus | C-type lectin, phosphotidylserine receptor | PAK1 | bCtBP-1/Bars | [ |
| Influenza A virus | RNA virus | Sialic acids | PAK1, Src | [ | |
| SGIV | DNA virus | PAK1, Rac1 | [ | ||
| ASFV | DNA virus | EGFR | PI3K-Akt, Rac1, PAK1 | [ | |
| HAdV-3 | DNA virus | CD46 and integrins | PAK1 | CtBP-1/fission and stabilization of macropinosome | [ |
| Vaccinia virus | DNA virus | MARCO, phosphotidylserine receptor | Cdc42 or Rac1, PAK1 | Actin rearrangement, formation of filopodia, membrane blebbing | [ |
| Bacteria | Type III secretion system stimulates macropinocytosis; no host cell entry occurs | SopE ( | JNK activation, membrane ruffling | [ | |
| Parasite | Rac1, PAK1 | [ |
Figure 3The bacterium Helicobacter pylori is a well-studied example of a pathogen manipulating host PAK1 signalling. (A) Upon infection of human epithelial cells, H. pylori activates Rac1 and stimulates recruitment of PAK1 to active Rac1 in a T4SS-dependent manner (pathway 1). H. pylori also induces interaction between PAK1 and NIK (pathway 2). Such interaction and subsequent phosphorylation of NIK by PAK1 have been proposed to be required for NF-κB activation in H. pylori infection [48]. Moreover, H. pylori is capable of stimulating NF-κB activation in a PAK1-dependent pathway through αPix (pathway 3). NF-κB activation and recruitment of PAK1 to active Rac1 both appear to require the T4SS, a complex macromolecular transporter and key virulence factor of H. pylori [48] (see BOX 2). CagA, the protein cargo of T4SS, has been shown to form a complex with αPix during H. pylori infection [137]. The T4SS is shown in red. Phosphorylation is indicated by the symbol “p”. Proteins identified to interact with PAK1 in H. pylori-infected epithelial cells are shown in yellow. (B) Upon stimulation of the human macrophage cell line, THP-1, purified H. pylori LPS can induce IL-1β secretion in a TLR4-dependent manner via post-translational (1) and transcriptional (2) pathways [138]. In the former pathway, H. pylori LPS stimulates Rac1 activity and the kinase activity of PAK1, triggering interaction of PAK1 with caspase-1 and possibly the subsequent phosphorylation of caspase-1 at S376 by PAK1. Phosphorylated caspase-1 then cleaves pro-IL-1β into mature active IL-1β. H. pylori LPS can also activate IL-1β expression at the transcriptional level via NF-κB-activation in a manner that requires the kinase activities of both PAK1 and IKKβ. It has been proposed that the up-regulation of IL-1β expression by H. pylori LPS involves the PI3K/Rac1/PAK1 signalling axis [138]. In-depth understanding of the molecular mechanism by which the kinase activity of PAK1 is modulated in these various pathways is warranted.